Response Genetics , Nasdaq: RGDX
Is developing diagnostic tests for assessing the risk of cancer recurrence and prediction of response to chemotherapy.
Industry: Health Care
First Day Return: 0.0%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 12/21/2006 |
| Offer Price | $7.00 |
| Price Range $7.00 - $8.00 | |
| Offer Shares (mm) | 3.0 |
| Deal Size ($mm) | $21 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 06/04/2007 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $21 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Los Angeles, CA, United States |
| Founded | 1999 |
| Employees at IPO | n/a |
| Website www.responsegenetics.com | |
Response Genetics (RGDX) Performance
